358 related articles for article (PubMed ID: 19460370)
41. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
42. Effects of intra-striatal GDNF on motor coordination and striatal electrophysiology in aged F344 rats.
Bowenkamp KE; Ujhelyi L; Cline EJ; Bickford PC
Neurobiol Aging; 2000; 21(1):117-24. PubMed ID: 10794856
[TBL] [Abstract][Full Text] [Related]
43. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.
Tseng JL; Baetge EE; Zurn AD; Aebischer P
J Neurosci; 1997 Jan; 17(1):325-33. PubMed ID: 8987758
[TBL] [Abstract][Full Text] [Related]
44. The effect of GDNF on nigrostriatal dopaminergic function in response to a two-pulse K(+) stimulation.
Xu K; Dluzen DE
Exp Neurol; 2000 Dec; 166(2):450-7. PubMed ID: 11085910
[TBL] [Abstract][Full Text] [Related]
45. Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system.
Romero-Ramos M; Venero JL; Garcia-Rodriguez S; Ayala A; Machado A; Cano J
Free Radic Res; 2003 Sep; 37(9):1003-12. PubMed ID: 14670008
[TBL] [Abstract][Full Text] [Related]
46. The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior.
Zaman V; Boger HA; Granholm AC; Rohrer B; Moore A; Buhusi M; Gerhardt GA; Hoffer BJ; Middaugh LD
Eur J Neurosci; 2008 Oct; 28(8):1557-68. PubMed ID: 18973577
[TBL] [Abstract][Full Text] [Related]
47. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Lindefors N; Brodin E; Tossman U; Segovia J; Ungerstedt U
Exp Brain Res; 1989; 74(3):527-34. PubMed ID: 2468514
[TBL] [Abstract][Full Text] [Related]
48. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms.
Reid MS; Herrera-Marschitz M; Hökfelt T; Lindefors N; Persson H; Ungerstedt U
Exp Brain Res; 1990; 82(2):293-303. PubMed ID: 1704847
[TBL] [Abstract][Full Text] [Related]
49. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.
Palfi S; Leventhal L; Chu Y; Ma SY; Emborg M; Bakay R; Déglon N; Hantraye P; Aebischer P; Kordower JH
J Neurosci; 2002 Jun; 22(12):4942-54. PubMed ID: 12077191
[TBL] [Abstract][Full Text] [Related]
50. Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration.
Cass WA; Walker DJ; Manning MW
Brain Res; 1999 May; 827(1-2):104-12. PubMed ID: 10320698
[TBL] [Abstract][Full Text] [Related]
51. Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity.
Lew JY; Garcia-Espana A; Lee KY; Carr KD; Goldstein M; Haycock JW; Meller E
Mol Pharmacol; 1999 Feb; 55(2):202-9. PubMed ID: 9927609
[TBL] [Abstract][Full Text] [Related]
52. Glial cell line-derived neurotrophic factor is crucial for long-term maintenance of the nigrostriatal system.
Nevalainen N; Chermenina M; Rehnmark A; Berglöf E; Marschinke F; Strömberg I
Neuroscience; 2010 Dec; 171(4):1357-66. PubMed ID: 20933580
[TBL] [Abstract][Full Text] [Related]
53. GFR α-1 receptor expression in the aging nigrostriatal and mesoaccumbens pathways.
Pruett BS; Salvatore MF
J Neurochem; 2010 Nov; 115(3):707-15. PubMed ID: 20731758
[TBL] [Abstract][Full Text] [Related]
54. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.
Granado N; Ares-Santos S; O'Shea E; Vicario-Abejón C; Colado MI; Moratalla R
Neurotox Res; 2010 Jul; 18(1):48-58. PubMed ID: 19760475
[TBL] [Abstract][Full Text] [Related]
55. CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Enna SJ; Reisman SA; Stanford JA
Neurosci Lett; 2006 Oct; 406(1-2):102-6. PubMed ID: 16890350
[TBL] [Abstract][Full Text] [Related]
56. Muscarinic receptors acting at pre- and post-synaptic sites differentially regulate dopamine/DARPP-32 signaling in striatonigral and striatopallidal neurons.
Kuroiwa M; Hamada M; Hieda E; Shuto T; Sotogaku N; Flajolet M; Snyder GL; Hendrick JP; Fienberg A; Nishi A
Neuropharmacology; 2012 Dec; 63(7):1248-57. PubMed ID: 22971543
[TBL] [Abstract][Full Text] [Related]
57. Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake.
Salvatore MF; Kasanga EA; Kelley DP; Venable KE; McInnis TR; Cantu MA; Terrebonne J; Lanza K; Meadows SM; Centner A; Bishop C; Ingram DK
Geroscience; 2023 Feb; 45(1):45-63. PubMed ID: 35635679
[TBL] [Abstract][Full Text] [Related]
58. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.
Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J
Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584
[TBL] [Abstract][Full Text] [Related]
59. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
60. Dichotomy of tyrosine hydroxylase and dopamine regulation between somatodendritic and terminal field areas of nigrostriatal and mesoaccumbens pathways.
Salvatore MF; Pruett BS
PLoS One; 2012; 7(1):e29867. PubMed ID: 22242182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
